The US Food and Drug Administration (FDA) has given its approval for the world’s inaugural chikungunya vaccine, recognizing the mosquito-borne virus as an “emerging global health threat.”
Chikungunya, a disease transmitted by mosquitoes, manifests with symptoms such as fever and joint pain, posing a potential threat, particularly to newborns, as it can be fatal. The FDA’s endorsement is anticipated to accelerate the global distribution of the vaccine.
As of September this year, approximately 440,000 cases of chikungunya, resulting in 350 deaths, have been reported worldwide. There is currently no specific pharmaceutical treatment for this disease, with South America and South Asia witnessing a higher incidence of cases.
The newly approved vaccine, named Ixchiq, developed by Valneva in Europe, is designed for individuals aged 18 and above who are at a heightened risk of contracting the disease. Administered in a single shot, the vaccine aims to address the severe health consequences associated with chikungunya.
Peter Marks, a senior FDA official, emphasized, “Infection with chikungunya virus can lead to severe disease and prolonged health problems, particularly for older adults and individuals with underlying medical conditions.”
Chikungunya has been responsible for at least five million reported cases since 2008, with symptoms extending beyond fever and joint pain to include rashes, headaches, and muscle pain. Joint pain can persist for months or even years.
Regions with tropical and subtropical climates in Africa, Southeast Asia, and parts of the Americas face the highest risk of infection due to the presence of mosquitoes carrying the chikungunya virus. The FDA highlighted that the virus has expanded its geographical reach, contributing to an elevated global prevalence.
Data from the European Centre for Disease Prevention and Control revealed Brazil’s highest reported cases this year, reaching 218,613. India, particularly Delhi, faced a significant outbreak in 2016, with over 93,000 cases reported.
The approval of the chikungunya vaccine marks a crucial step in addressing the growing global health challenge posed by the virus.
